Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease
Advanced Materials · 2023-12 · 35 (51)
DOI: 10.1002/adma.202304654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 27.10.2023. Verfasst von Mor Sela und 35 weiteren Autor:innen. Beteiligte Einrichtung: The Louis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel …. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Research Council, NIA NIH HHS, Israel National Institute for Health Policy Research.
Abstract (Originalsprache)
Monoclonal antibodies (mAbs) hold promise in treating Parkinson's disease (PD), although poor delivery to the brain hinders their therapeutic application. In the current study, it is demonstrated that brain‐targeted liposomes (BTL) enhance the delivery of mAbs across the blood‐brain‐barrier (BBB) and into neurons, thereby allowing the intracellular and extracellular treatment of the PD brain. BTL are decorated with transferrin to improve brain targeting through overexpressed transferrin‐receptors on the BBB during PD. BTL are loaded with SynO4, a mAb that inhibits alpha‐synuclein (AS) aggregation, a pathological hallmark of PD. It is shown that 100‐nm BTL cross human BBB models intact and are taken up by primary neurons. Within neurons, SynO4 is released from the nanoparticles and bound to its target, thereby reducing AS aggregation, and enhancing neuronal viability. In vivo, intravenous BTL administration results in a sevenfold increase in mAbs in brain cells, decreasing AS aggregation and neuroinflammation. Treatment with BTL also improve behavioral motor function and learning ability in mice, with a favorable safety profile. Accordingly, targeted nanotechnologies offer a valuable platform for drug delivery to treat brain neurodegeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Louis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion - Israel Institute of Technology, Haifa, 32000, Israel.
- The Norman Seiden Multidisciplinary Program for Nanoscience and Nanotechnology, Technion - Israel Institute of Technology, Haifa, 32000, Israel.
- The Interdisciplinary Program for Biotechnology, Technion - Israel Institute of Technology, Haifa, 32000, Israel.
- School of Neurobiology, Biochemistry and Biophysics, George S. Wise Faculty of Life Sciences, Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, 6997801, Israel.
- Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, 6997801, Israel.
- Department of Occupational Therapy, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, 3498838, Israel.
ORCID-Profile: Avi Schroeder
Förderung
- European Research Council
- NIA NIH HHS
- Israel National Institute for Health Policy Research
- Michael J. Fox Foundation for Parkinson's Research
- Teva Pharmaceutical Industries
- Phospholipid Research Center
- Israel Science Foundation
Zitieren
APA
Sela, M., Poley, M., Mora-Raimundo, P., Kagan, S., Avital, A., Kaduri, M., Chen, G., Adir, O., Rozencweig, A., Weiss, Y., Sade, O., Leichtmann-Bardoogo, Y., Simchi, L., Aga-Mizrachi, S., Bell, B., Yeretz-Peretz, Y., Or, A. Z., Choudhary, A., Rosh, I., …, & Schroeder, A. (2023). Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease. Advanced Materials, 35(51). https://doi.org/10.1002/adma.202304654
Vancouver
Sela M, Poley M, Mora-Raimundo P, Kagan S, Avital A, Kaduri M, et al. Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease. Advanced Materials. 2023;35(51). doi:10.1002/adma.202304654
BibTeX
@article{Sela2023,
author = {Sela, Mor and Poley, Maria and Mora-Raimundo, Patricia and Kagan, Shaked and Avital, Aviram and Kaduri, Maya and Chen, Gal and Adir, Omer and Rozencweig, Adi and Weiss, Yfat and Sade, Ofir and Leichtmann-Bardoogo, Yael and Simchi, Lilach and Aga-Mizrachi, Shlomit and Bell, Batia and Yeretz-Peretz, Yoel and Or, Aviv Zaid and Choudhary, Ashwani and Rosh, Idan and Cordeiro, Diogo and Cohen-Adiv, Stav and Berdichevsky, Yevgeny and Odeh, Anas and Shklover, Jeny and Shainsky-Roitman, Janna and Schroeder, Joshua E and Hershkovitz, Dov and Hasson, Peleg and Ashkenazi, Avraham and Stern, Shani and Laviv, Tal and Ben-Zvi, Ayal and Avital, Avi and Ashery, Uri and Maoz, Ben M and Schroeder, Avi},
title = {Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease},
journal = {Advanced Materials},
year = {2023},
volume = {35},
number = {51},
doi = {10.1002/adma.202304654}
}
EUVIMED